Titan Corporation

Titan Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the development of long-term, continuous drug delivery therapeutics using its proprietary ProNeura platform. The ProNeura technology utilizes a subdermal ethylene-vinyl acetate (EVA) matrix implant to provide stable medication levels for up to six months, aiming to improve patient compliance and outcomes in chronic conditions. The company's lead product, Probuphine (buprenorphine implant), was the first subdermal implant approved for the maintenance treatment of opioid use disorder. In October 2025, the company completed a transformative merger with Black Titan Corporation and TalenTec, transitioning into a subsidiary of Black Titan (Nasdaq: BTTC). Titan's current development pipeline includes TP-2021, a kappa opioid receptor agonist for chronic pruritus, along with programs for migraine prophylaxis and schizophrenia.